Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention

Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention

Abstract Background New COVID-19 treatments are desperately needed as case numbers continue to rise and emergent strains threaten vaccine efficacy. Cell therapy has revolutionized cancer treatment and holds much promise in combatting infectious disease, including COVID-19. Invariant natural killer T...

Full description

Bibliographic Details
Main Authors: Yan-Ruide Li, Zachary Spencer Dunn, Gustavo Garcia, Camille Carmona, Yang Zhou, Derek Lee, Jiaji Yu, Jie Huang, Jocelyn T. Kim, Vaithilingaraja Arumugaswami, Pin Wang, Lili Yang
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Stem Cell Research & Therapy
Subjects:
Hematopoietic stem cell (HSC)
Invariant natural killer T (iNKT) cell
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Allogeneic adoptive cell transfer
Off-the-shelf cellular product
Online Access:https://doi.org/10.1186/s13287-022-02787-2

Internet

https://doi.org/10.1186/s13287-022-02787-2

Similar Items